Heart failure & cardiomyopathiesResearch article
Cost-Effectiveness of Dapagliflozin for Patients with Heart Failure Across the Spectrum of Ejection Fraction: A Pooled Analysis of DAPA-HF and DELIVER Data
- Cost-effectiveness analysis (pooled patient-level analysis of the DAPA-HF and DELIVER trials)
- lifetime horizon Markov model
- UK setting
Authors' conclusion
Dapagliflozin plus usual care, versus usual care alone, yielded results well below the WTP threshold for the UK across a heterogeneous population of patients with HF including the full spectrum of LVEF, and is likely a cost-effective intervention.
Study context
- Population
- Patients with heart failure (HF) across the full range of left ventricular ejection fraction (LVEF) (reduced, mildly reduced and preserved)
- Comparison
- Dapagliflozin plus usual care vs usual care alone
- Outcome
- ICER (cost per QALY gained)
- Follow-up
- Lifetime horizon
Main finding
As reported in the abstract
Base case ICER
Base case incremental cost-effectiveness ratio (ICER), dapagliflozin + usual care vs usual care alone (UK willingness-to-pay (WTP) threshold £20 000/quality-adjusted life year (QALY) gained)
£6470 per QALY gained
Further findings
ICER in interaction sensitivity analyses
- Highest ICER: elderly patients with preserved LVEF
- £16 624/QALY gained
- Mostly across the patient characteristic interaction plane
- between £5000 and £10 000/QALY gained
- Dominance (increased QALYs, decreased costs) for poorer renal function and reduced/mildly reduced LVEF
Original publication
Cost-Effectiveness of Dapagliflozin for Patients with Heart Failure Across the Spectrum of Ejection Fraction: A Pooled Analysis of DAPA-HF and DELIVER Data. Eur J Heart Fail. Published 20 March 2024. doi:10.1002/ejhf.3197
Summarised from the published abstract; every number is checked against it